Globalization of the Pharmaceutical Industry and the Growing Dependency of Developing Countries: The Case of Turkey

Abstract

In developing countries, the effect of globalization on the pharmaceutical sector has resulted in a decrease in exportation and domestic production, accompanied by an increase in importation of pharmaceuticals and a rise in prices and expenditures. As an example of a developing country, Turkey has been facing the long-standing and increasing pressure of global regulations placed on its pharmaceutical sector. This has led to an increasing dependency on multinational companies and a gradual deterioration of an already weakened domestic pharmaceutical sector. This case study of Turkey offers points to consider in the world of increasing globalization, as it offers lessons on ways of examining the effects of globalization on the pharmaceutical industry of developing countries.

Get full access to this article

View all access options for this article.

References

World Health Organization. The World Medicines Situation. 2004. WHO/EDM/PAR/2004.5. www.who.int/medicines/organization/par/World_Medicines_Situation.pdf (December 10, 2004).

Combe

, and Zuniga

Introducing Patent Protection in the Pharmaceutical Sector: A First Evaluation for the Mexican Case. 2002. www.intech.unu.edu/events/conferences/ceres_15may2002/zuniga.pdf (April 14, 2004).

Erdut

Küresellesme Baglaminda Uluslararasi Sosyal Politika ve Turkiye. Dokuz Eylul Yayinlari, Izmir, 2002.

NTV. Turkiye 22. Büyük ekonomi, 2004. www.ntvmsnbc.com/news/267135.asp (December 11, 2004).

Savas

In Health Care Systems in Transition: Turkey, ed. Thomson

and Mossialos

. European Observatory on Health Care Systems, 4(4). Copenhagen, 2002.

United Nations Development Program. Human Development Report. 1994. http://hdr.undp.org/reports/view_reports.cfm?type=1 (August 11, 2003).

United Nations Development Program. Human Development Report. 2004. http://hdr.undp.org/reports/view_reports.cfm?type=1 (April 12, 2004).

Semin

Sosyal ve Ekonomik Yönleriyle Ilac TTB Yayinlari, Ankara, 1998.

Kirim

A. S.

The Internationalisation of Capital and Industrialisation in the Third World: A Case Study of Turkish Pharmaceutical Industry towards Appraising the Oligopoly Approach to Transnational Corporations. Ph.D. thesis, University of East Anglia, UK, 1985.

10.

World Bank. Turkey—Reforming the Health Sector for Improved Access and Efficiency. Report No. 24358-TU. Washington, DC, 2003.

11.

Türkiye Isveren Sendikalari Konfederasyonu. Ilac Sektöründe Veri imtiyazi. Isveren. Ocak, 2004. www.tisk.org.tr/isveren_sayfa.asp?yazi_id=881&id=51 (May 19, 2004).

12.

Balasubramaniam

Access to Medicines and Public Policy Safeguards under TRIPS. Bangladesh, 2002. www.ictsd.org/dlogue/2002–04–19/Balasubramaniam.pdf (May 26, 2004).

13.

Baker

, and Chatani

Promoting Good Ideas on Pharmaceuticals: Are Patents the Best Way? The Relative Efficiency of Patent and Public Support for Bio-Medical Research. 2002. www.cepr.net/promoting_good_ideas_on_pharmaceuticals.htm (July 18, 2003).

14.

Coriat

, and Orsi

AIDS and TRIPS Pharmaceutical Patents, Generic Pharmaceuticals and Public Health under the TRIPS. 2003. www.business.auc.dk/druid/conferences/summer2003/papers/CORIAT_ORSI.pdf (June 26, 2004).

15.

Alavi

The Impact of the TRIPS on the Malaysian Pharmaceutical Industry. 2001. http://phuakl.tripod.com/pssm/conference/RokiahAlavi.doc (June 26, 2004).

16.

Balasubramaniam

Globalisation Liberalisation of Healthcare Services: WTO and the General Agreement on Trade in Services. 2000. www.phmovement.org/pubs/issuepapers/bala2.html (October 14, 2003).

17.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Ilac ve ilac endustrisi. Alas Basimevi, Istanbul, 1984.

18.

Matraves

Market Structure, R&D and Advertising in the Pharmaceutical Industry. September 1998. skylla.wz-berlin.de/pdf/1998/iv98–17.pdf (June 11, 2003).

19.

ABPI. Facts and Statistics from the Pharmaceutical Industry. 2004. www.abpi.org.uk/statistics/section.asp?sect=1 (October 16, 2004).

20.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Pharmaceuticals in Turkey. 1984–2003. www.ieis.org/tr/yayin/index2.htm (November 22, 2004).

21.

Kaplan

Yasadigimiz surec. 2003. www.istanbuleczaciodasi.org.tr/baskankose/yazidetay.asp?id=41 (September 16, 2004).

22.

Supakankunti

Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand. Bull. World Health Org. 79(5):461–470, 2001.

23.

Correa

Review of the TRIPS Agreement: Fostering the Transfer of Technology to Developing Countries. Current Developments in the WTO: Perspective of Developing Countries. 2000. www.twnside.org.sg/title/foster.htm (July 15, 2004).

24.

Kaplan

W. A.

Is Local Production of Pharmaceuticals a Way to Improve Pharmaceutical Access in Developing and Transitional Countries? Setting a Research Agenda. 2003. www1.worldbank.org/hnp/hsd/documents/LOCALPRODUCTION.pdf (June 16, 2004).

25.

Kanzik

Turk ilac Sanayiinin AB cercevesinde SWOT Analizi. Genel kurul. 2001. www.ieis.org/tr/toplanti/swot.htm (July 24, 2003).

26.

U.S. Trade Representative. National Trade Estimate Report on Foreign Trade Barriers. 2006. www.bilaterals.org/article.php3?id_article=4338 (October 14, 2006).

27.

Abrol

Knowledge Diffusion under the Emerging Post-TRIPS Indian Pharmaceutical Scenario. 2004. www.druid.dk/ocs/viewabstract.php?id=206&cf=1 (October 16, 2004).

28.

Adana Eczaci Odasi. Basin Aciklamasi. May 14, 2004. www.adanaeo.org.tr/duyuru/oku.asp?id=152 (June 26, 2004).

29.

ITO. Ilaç politikamiz Avrupa Birligi'ne emanet. 2004. www.istabip.org.tr/bg/2004/069.html (November 22, 2005).

30.

Veri imtiyazi 1 ocak 2005'ten itibaren. 1 Subat. Tip Dunyasi. Sayi, 131, 2005. www.ttb.org.tr/TD/TD131/19.php3 (February 4, 2005).

31.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Ilac Endustrisinin son 5 yillik gostergeleri. Rapor 114:2–5, 2003.

32.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Industry. www.ieis.org/eng/endustri/index2.htm (December 23, 2006).

33.

Foreign Economic Relations Board. Pharmaceutical Industry. 2003. www.deik.org.tr/bultenler/2003320154019sectors-pharmaceutical-june02.pdf (June 16, 2004).

34.

Ucer

Dünya Olceginde Avrupa Ilac Endustrisi ve Turkiye'nin Gerileyen Yeri. Universite ve Toplum. Mart, 2003. www.universite=toplum.org/text.php3?id=116 (October 12, 2004).

35.

Ibrahim

Abdi

. Abdi Ibrahim Ilac Yurtdisinda Yeni Pazarlara Aciliyor. 2004. www.abdiibrahim.com.tr/haberler/haber_07062004.asp.

36.

Timmermas

, and Hutadjulu

The TRIPS Agreement and Pharmaceuticals: Report of an ASEAN Workshop on the TRIPs Agreement and Its Impact on Pharmaceuticals. May 2000. www.who.int/medicines/library/dap/aseantripsagreement.pdf (October 2, 2003).

37.

Commission on Intellectual Property Rights. Integrating Intellectual Property Rights and Development Policy. 2002. www.eldis.org/static/DOC10305.htm (July 26, 2004).

38.

Semin

Guldal

, and Demiral

Globalization and the trends of medical technology trade in Turkey. Health Policy, August 5, 2006 [Epub ahead of print].

39.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Ilac 1989 101 soru101 yanit. Istanbul, 1989.

40.

Adana Eczaci Odasi. Ithal ilac bildirim formu. 2004. www.adanaeo.org.tr/duyury/oku.asp?id=137 (October 2, 2004).

41.

Ayaz

SSK ve ilac Ortak Kullanim piyasalar. Hekimden Hekime. Kis, 2004, pp. 39–41.

42.

Bursa Eczaci Odasi. Ilaçta duble kazik. 2003. www.beo.org.tr/basin/basinecz.htm.

43.

DPT. Ilaç sanayi ozel ihtisas komisyon raporu. OK. 556. Ankara, 2001.

44.

U.N. Conference on Trade and Development. Statistics: Overview. 2004. www.unctad.org/Templates/Page.asp?intItemID=1584&lang=1.

45.

Food and Pharmaceutical Control Administration. PharmaceuticalIndustry_in_Gujarat. 2001. www.gujhealth.gov.in/FDCA/salient.htm (January 20, 2004).

46.

U.N. Conference on Trade and Development. Strengthening Participation of Developing Countries in Dynamic and New Sectors of World Trade. 2004. www.unctad.org/Templates/Page.asp?intItemID=1397&lang=1 (October 11, 2004).

47.

U.N. Conference on Trade and Development. Development and Globalization: Facts and Figures. 2004. www.unctad.org/Templates/Page.asp?intItemID=1584&lang=1 (December 14, 2004).

48.

World Trade Organization. International Trade Statistics 2003. 2004. www.wto.org/english/rese/statise.htm (October 14, 2004).

49.

Eren

The Transnationalization of Turkish Pharmaceutical Industry. Ph.D. thesis, University of Sussex, Institute of Development Studies, UK, 2002.

50.

Beseri Tibbi Urünlerin Fiyatlandirilmasina Dair Karar. Resmi gazete. 14 nisan: 25433. 2004.

51.

Semin

Aras

, and Guldal

Direct-to-consumer advertising of pharmaceuticals: Developed countries experiences and Turkey. Health Expectations 10(1):4–15, 2007.

52.

Kaplan

Yeni Ilaç Fiyat Kararnamesi Kaos Yaratacak. 2004. www.farmamedya.com/index.php?module=haberler&num=139 (October 22, 2004).

53.

Sahin

Abartilan gecici ucuzluk. 2004. www.radikal.com.tr/haber.php?haberno=121532 (October 26, 2004).

54.

Talu

Bayilana ilac, ayilana indirim. Sabah, June 17, 2004.

55.

Akdag

Ucuz ilac serap mi?

Aksiyon, 2004, p. 495. www.aksiyon.com.tr/detay.php?id=11547&yorum_id=1.

56.

Kisa

The performance and problems of the Turkish pharmaceutical industry: Is there a need to develop a national pharmaceutical policy?

J. Med. Syst. 25(5):309–318, 2001.

57.

Engelberg

Implementing the Doha Declaration: A Potential Strategy for Dealing with Legal and Economic Barriers to Affordable Medicines. 2002. www.cptech.org/ip/health/pc/engelberg.html.

58.

Government of Turkey, Ministry of Health. Pharmaceutical Prices. 2004. www.saglik.gov.tr/sb/default.asp?sayfa=birimler&cid=1&sid=977 (July 22, 2004).

59.

Ernst & Young. The Global Marketplace. 2002. www.ey.com/…/International/Global_Pharmaceutical_marketplace/$file/E&YGlobalPharmaMarket.pdf (May 28, 2003).

60.

Generic Pharmaceutical Association. Generic Pharmaceutical Facts at a Glance. 2004. www.gphaonline.org/aboutgenerics/factsabout.html (July 23, 2004).

61.

European Generic Medicines Association. The Use of Generic Medicines in Europe. 2004. www.egagenerics.com/fac-hcmarkets.htm.

62.

Ucer

Referans Fiyat Uygulamasi. March 3, 2004. www.guvercinevi.net/yazilar.asp?ID=581 (May 23, 2005).

63.

Serimer

Ilac fiyatlari hakkinda bir arastirma. TEB Haberler 33:12, 1987.

64.

Central Bank of the Republic of Turkey. Consumer Price Index. 2004. http://tcmbf40.tcmb.gov.tr/cbt.html (September 30, 2004).

65.

Angell

The truth about the pharmaceutical companies. New York Review of Books 51(12), July 15, 2004. www.nybooks.com/articles/17244.

66.

Public Citizen. America's Other Pharmaceutical Problem: A Briefing Book on the Rx Pharmaceutical Debate. 2003. www.citizen.org/documents/dbbapril.pdf (January 2, 2004).

67.

Harris

Pharmaceutical companies seek to mend their image. New York Times, July 8, 2004.

68.

Istanbul Chamber of Industry. 500 major industrialist enterprises of Turkey. Istanbul Chamber of Industry Journal 342, September 1994.

69.

Istanbul Chamber of Industry. 500 major industrialist enterprises of Turkey. Istanbul Chamber of Industry Journal 354, September 1995.

70.

Istanbul Chamber of Industry. 500 major industrialist enterprises of Turkey. Istanbul Chamber of Industry Journal 449, August 2003.

71.

Istanbul Chamber of Industry. 500 major industrialist enterprises of Turkey. Istanbul Chamber of Industry Journal 461, August 2004.

72.

Aktan

, and Ozkivrak

. Türkiye'de 500 buyuk firma arasinda kamu ve ozel sektor perfomans karsilastirmasi. 2000. www.canaktan.org/ekonomi/ozellestirme/devletpiyasa-karsilastirma/besyuz-buyuk-firmada-karsilastirma.htm (May 22, 2004).

73.

Domac

Ilac fiyat artislari ve ilac firmalarinin karliligi. Havan 6:32–37, 1990.

74.

Dhar

, and Rao

Transfer of Technology for Successful Integration in the Global Economy: A Case Study of Pharmaceutical Industry in India. UNCTAD/ITE/IPC/Misc.22. UNCTAD, 2002.

75.

IEIS (Pharmaceutical Manufacturer Association of Turkey). 101 soruda ilac endustrisi. 2002. www.ieis.org/tr/endustri/sinif.htm (May 16, 2004).

76.

Koktug

Saglik hizmetlerinde disa bagimlilik. Toplum ve Hekim 30:17–26, 1980.

77.

Tam vergi veren yok. Radikal, April 22, 2004.

78.

Santoso

Financing Pharmaceuticals in South-East Asia. Report of the second meeting of the WHO/SEARO Working Group on Pharmaceutical Financing WHO/DAP/98.15. Geneva, 1998.

79.

IMS. Lipitor leads the way in 2003. 2004. www.ims-global.com/insight/news_story/0403/news_story_040316.htm (October 14, 2004).

80.

Akyildiz

2003 Yilinda ilac Pazari. Hedef Saglik, Sayi 17, 2004. www.hedefim.com/v3/hs/18/10.asp (December 23, 2004).

81.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Ilaç kullanim oranlari. Rapor 115, 2004. www.ieis.org/tr/yayin/index2.htm (October 14, 2004).

82.

Tokat

Turkiye Saglik Harcamalari ve Finansmani 1998. Saglik Bakanligi, Saglik Projesi Genel Koordinatorlugu, Ankara, 2001.

83.

DPT. Ekonomik ve sosyal göstergeler (1950–2003). http://ekutup.dpt.gov.tr/ekonomi/gosterge/tr/ (March 19, 2004).

84.

IEIS (Pharmaceutical Manufacturer Association of Turkey). Aylik Rapor 36–37, 1991.

85.

Espicom Business Intelligence. World Pharmaceutical Markets France. 2002. http://news.investinfrance-nordic.org/l/txt/Pharma%20in%20France.pdf (May 23, 2004).

86.

VFA (German Associations of Research Based Pharmaceutical Companies). The Pharmaceutical Market in Germany. 2003. www.vfa.de/en/statistics/pharmaceuticalmarket/ (December 9, 2004).

87.

Miller

R. D.

Jr. , and Frech

H. E.

Is there a link between pharmaceutical consumption and improved health in OECD countries?

Pharmacoeconomics 18 (Suppl. 1):33–45, 2000.

88.

Baykara

, ve ark. Türkiye' de Ilacta Veri Korumasi ve Uygulamasinin Mali Etkileri. 2003. www.aifd.org.tr/tr/detay.asp?ID=75&db=sektorun_sorunlari (May 21, 2004).

89.

Anderson

G. F.

Petrosyan

, and Hussey

P. S.

Multinational Comparisons of Health Systems Data. 2002. www.cmwf.org/programs/international/anderson_multinationalcomparisons2002_582.pdf (October 14, 2004).

90.

OXFAM. Fatal Side Effects: Medicine Patents under the Microscope. 2001. www.oxfam.org.uk/what_we_do/issues/health/fatal_side_effects.htm (October 4, 2003).

91.

Navarro

Why some countries have national health insurance, others have national health services, and the U.S. has neither. Int. J. Health Serv. 19:383–404, 1989.